KISSEI

  • Link
  • Japanese Page

Change Font Size

  • normal
  • large
  • About Kissei
  • Research & Development
  • News Release
  • Investor Relations
  • Sustainability

About Kissei

Research & Development

News Release

Investor Relations

Sustainability

kissei

  • About Kissei
  • Research & Development
  • News Release
  • Investor Relations
  • Sustainability
  • Link
  • Japanese Page
  • English
  • Message
  • Philosophy
  • Company Profile
  • Our Business
  • KISSEI's History
  • Corporate Governance
  • About R&D
  • Central Research Laboratories
  • Safety Research Laboratories
  • Joetsu Chemical Laboratories
  • Pharmaceutical Laboratories
  • R&D Pipeline
  • Business Results
  • Annual Report
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • CSR Management
  • SDGs
  • Materiality
  • Compliance
  • Social Contribution Activities
  • Environmental Initiatives
  • Consideration for Employees
  • ESG Data
  • Message
  • Philosophy
  • Company Profile
  • Our Business
  • KISSEI's History
  • Corporate Governance
  • About R&D
  • Central Research Laboratories
  • Safety Research Laboratories
  • Joetsu Chemical Laboratories
  • Pharmaceutical Laboratories
  • R&D Pipeline
  • Business Results
  • Annual Report
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • CSR Management
  • SDGs
  • Materiality
  • Compliance
  • Social Contribution Activities
  • Environmental Initiatives
  • Consideration for Employees
  • ESG Data
  • English Home
  • News Release
  • News Release(2020)

News Release(2020)

2020

  • December 10, 2020

    The Efficacy and Safety Results of the Overseas Phase-III Long-Term Study of Uterine Fibroids for GnRH Antagonist, Linzagolix, conducted by ObsEva

  • October 9, 2020

    Licensing Agreement with Affamed for KDT-3594, a Novel Investigational Drug for Parkinson's Disease

  • July 6, 2020

    Positive Results from Uterine Fibroids Phase-III Clinical Trials (PRIMROSE 1 and PRIMROSE 2) of Linzagolix

  • March 27, 2020

    Licensing Agreement for CG0070, a Drug for Bladder Cancer

  • February 25, 2020

    Transfer of Distribution Operation of MINIRIN MELT® and DESMOPRESSIN Formulations

  • February 3, 2020

    Transfer of Distribution Operation of MARIZEV® Type-2 Diabetes Treatment

  • January 22, 2020

    Kissei Announces the Publication of the Results of Phase III Clinical Trials of Rovatirelin for the Treatment of Spinocerebellar Degeneration in the Journal of Neurology, Neurosurgery, and Psychiatry

  • About Kissei
  • Research & Development
  • News Release
  • Investor Relations
  • Terms of Use
  • Privacy Policy
© 2012- Kissei Pharmaceutical Co., Ltd. All rights reserved.
キッセイ薬品工業株式会社

Thank you for visiting the Kissei website.
You are now moving to an external website.
(A new window will be opened.)

Access the link